Navigation Links
Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
Date:1/7/2008

prove smoking cessation rates could have a good opportunity for a quick market penetration and provide an additional treatment tool for physicians.

Forward looking statements

Information set forth in this report contains forward-looking statements, which involve a number of risks and uncertainties. Such forward-looking statements include, but are not limited to, statements about the anticipated benefits of Evotec's products, the timing of the completion of the transaction between Evotec and Renovis, the anticipated benefits of the business combination transaction involving Evotec and Renovis, including future financial and operating results, the combined company's plans, objectives, expectations and intentions, the anticipated timing and results of the combined company's clinical and pre-clinical programs, and other statements that are not historical facts. Evotec cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. These include risks and uncertainties relating to: the ability to obtain regulatory approvals of the transaction on the proposed terms and schedule; the parties' ability to complete the transaction because conditions to the closing of the transaction may not be satisfied; the failure to successfully integrate the businesses; unexpected costs or liabilities resulting from the transaction; the risk that synergies from the transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; gener
'/>"/>

SOURCE Evotec AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
2. Oncolytics Biotech Inc. Announces Filing of Phase 1/2 Clinical Trial with REOLYSIN(R)
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. Oncolytics Biotech Inc. Completes Patient Enrolment in U.K. Phase Ia/Ib Combination REOLYSIN(R)/Radiation Clinical Trial
5. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
6. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
7. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
8. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
9. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
10. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
11. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... HILL, N.C. , Dec. 22, 2014 /PRNewswire/ ... today announced that it has signed a letter ... company that has developed and patented a nanotechnology-based ... medical diagnostics products that enable rapid on-site collection ... alcohol use/abuse and health issues in an immediate, ...
(Date:12/22/2014)... ITRA Global, one of the largest organizations dedicated ... has further expanded its global reach with the affiliation ... Australia, reports Mylinda Vick, CCIM, Chairman of the ITRA ... ACORPP (Australian Corporate Property and Projects) , is a ... to a wide range of clients in the private ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of the nation’s ... Pharm.D. to the newly created position of Vice President ... Dr. Maroulis will continue to manage the entire specialty ... pharmacies as the company expands. Dr. Maroulis has been ... has served in many different capacities in the pharmacy, ...
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources Group ... grow at a 12 percent compound annual growth rate ... the aging population and the increasing adoption of dental ... will also spur demand for dental biomaterials ... implant and periodontal treatments. Other key findings ...
Breaking Biology Technology:ALNE Announces Intention To Acquire BioTechPharma 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... facility to support clinical development for ... lead drug candidate and other molecules, ... radiopharmaceutical company that designs, develops and,manufactures products to detect, ... completed commissioning its in-house manufacturing,capability to meet clinical trial ...
... (OTC Bulletin Board: YGYB) ("Yongye" or the "Company"),a leading ... in the People,s Republic of China, today announced its ... Second Quarter 2008 Highlights -- Revenue was ... quarter of 2007, and an ...
... 15 The backpack is a back-to-school,staple. In ... fashion accessory as,well. However, backpacks are a leading ... children and adolescents. As students head back to ... preventing,unnecessary backpack pain and injuries., The MCA ...
Cached Biology Technology:Cellectar, Inc. Begins GMP Production 2Yongye Biotechnology International Announces Second Quarter Results 2Yongye Biotechnology International Announces Second Quarter Results 3Yongye Biotechnology International Announces Second Quarter Results 4Yongye Biotechnology International Announces Second Quarter Results 5Yongye Biotechnology International Announces Second Quarter Results 6Yongye Biotechnology International Announces Second Quarter Results 7Yongye Biotechnology International Announces Second Quarter Results 8Yongye Biotechnology International Announces Second Quarter Results 9Yongye Biotechnology International Announces Second Quarter Results 10Yongye Biotechnology International Announces Second Quarter Results 11Minnesota Chiropractic Association Offers Backpack Safety Checklist 2
(Date:12/10/2014)... , December 9, 2014 ... ITN,s BCARD Platform   ... enterprise meeting scheduling solutions for business-to-business (B2B) events, ... world leader in mobile near-field communication (NFC), Bluetooth ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow ...
(Date:12/5/2014)...  Tute Genomics, a leader in cloud-based solutions for ... funding led by UK-based Eurovestech. Peak Ventures and a ... round. "We are at a pivotal time ... and seeks new approaches for the diagnosis, treatment and ... MBA, and CEO of Tute Genomics. "One of the ...
(Date:12/3/2014)...   Marvin Test Solutions , a trusted ... military, aerospace, and manufacturing organizations, today announced the ... TS-900 PXI semiconductor test platform . The TS-960 ... to customers at a fraction of the footprint ... "Our semiconductor customers asked for ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... Romeo Casabona is Director of the Interuniversity Professorship in Law ... of the Basque Country. The Professorship is largely made up ... in the fields of molecular biology, medicine and even specialists ... Humane Genome at the Universities of Deusto and the Basque ...
... , This release is available in German ... less than half accumulate in the atmosphere where it contributes ... and terrestrial ecosystems such as forests, grasslands and peat-lands. Stimulating ... one of the main, immediately available ways of reducing climate ...
... deletion can increase the likelihood of immune complications following ... in the November 22 advance online issue of ... missing from the donor,s genome but present in the ... serious side-effect known as graft-versus-host disease, in which immune ...
Cached Biology News:Research and legislation should go hand in hand, as much as possible 2Intensive land management leaves Europe without carbon sinks 2Gene mismatch influences success of bone marrow transplants 2Gene mismatch influences success of bone marrow transplants 3Gene mismatch influences success of bone marrow transplants 4
Kinase Buffer can be used to assay protein kinase activity...
Goat polyclonal to SPFH2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: EDEPLETATKEN, corresponding to C terminal amino acids 328-339 of Human SPFH2 Entrez Gene ID: 11...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Biology Products: